Good summary this is one I’m watching Pfizer did stop...

First 596 Last

Share
Profile

Follow
vrs37

437 Posts.

211

26/09/20

09:43

Post #: 47645780
Share

Originally posted by SteadyEddie: ↑

Thanks for the detailed analysis OvF. As a medico I thought I'd jump in and clarify some things for others.
Facts so far -
In FSGS: Orphan Drug status for DMX- 200 in FSGS was gained in December 2015. The recent FSGS trial results announced 29 July showed that DMX-200 drug works is patients with deteriorating kidney function reducing the rate of albuminuria ( protein loss in the urine) by average 29%. The mechanism of action is thought to be reducing damaging levels of inflammation. The average starting level of proteinuria in this group was 411mg/mmol - remember this number.... If you can reduce proteinuria you can delay / prevent the need to go on dialysis at cost $100,000 per year. Having orphan drug status means potentially you can charge up to about $80,000 per year per patient for DMX-200. Multiply that by the 80,000 patients with FSGS in USA and you get big numbers. The recent diabetic trial doesn't change any of these numbers.
Looking at Diabetic kidney disease (DKD): inclusion criteria same as earlier trials proteinuria >30mg/mmol, overall result not significantly better than placebo. BUT - still positive result in those with more serious disease > 57mg/mmol (18% improvement). In previous studies only patients with much higher levels of proteinuria actually joined the trials but in this study there were a significant proportion with only mild disease. Thus it seems that it works in more serious disease only. This is consistent with the FSGS trial - remember the average 411mg/mmol entry level for patients - much higher than the DKD trial. This is useful information to proceed to the phase 3 trial - patients with mild disease will be excluded. The market is still huge for severe disease. Looking forward to reading the in depth analysis by researchers.

My conclusion - DMX-200 appears to be an effective anti-inflam agent in mod - severe kidney disease - but we still need confirmation with a larger phase 3 trial.

Covid: study yet to start for DMX-700 - similar mechanism of action to reduce excessive inflammation without side effects associated with steroids.

Expand

Good summary
this is one I’m watching
Pfizer did stop development of their Ccr2i due to insufficient benefit in kidney disease but this DXB product might be better.
agree best go for moderate/ high albuminuria group.
not sure why they did the cut at 500 unless that was prespecified otherwise looks arbitrary.
test will be whether in phase 3 it protects not just kidney but also reduces cardiac endpoints, maybe even additive to AZ’s farxiga?

DXB Price at posting: 24.5¢ Sentiment: None Disclosure: Not Held
9 Upvote

0 Great analysis

Reply

Top Stories

AL8

From the Floor question: "What is the focus of AL8 and how is management going to attract shareholders to the registry?" | Alderan Resources

SXG

From the Floor question: "Could gold be manufactured in a lab like diamonds?"

CC9

The USA's dominance requires a domestic lithium supply chain. Chariot stands to benefit

FEX

From the Floor question: "When will FEX start using rail to augment & de-risk their haulage solution?" | Fenix Resources

Chris Judd's Talk Ya Book: Tracking Life360 on a journey to the stars

There are more pages in this discussion • 32 more messages in this thread...

First 596 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 55.5¢		Change -0.015(2.63%)		Mkt cap ! $305.1M

Open	High	Low	Value	Volume
56.0¢	58.5¢	54.0¢	$3.231M	5.779M

Buyers (Bids)

No.	Vol.	Price($)
1	1118	55.5¢

Sellers (Offers)

Price($)	Vol.	No.
56.5¢	239062	1

View Market Depth

No.	Vol.	Price($)
1	1118	0.555
3	56053	0.550
6	111652	0.545
15	259396	0.540
4	69275	0.535

Price($)	Vol.	No.
0.565	239062	1
0.570	95670	3
0.575	33246	2
0.580	11000	1
0.585	74555	5

Last trade - 16.10pm 19/06/2024 (20 minute delay)

DXB (ASX) Chart

Good summary this is one I’m watching Pfizer did stop...

From the Floor question: "What is the focus of AL8 and how is management going to attract shareholders to the registry?" | Alderan Resources

From the Floor question: "Could gold be manufactured in a lab like diamonds?"

The USA's dominance requires a domestic lithium supply chain. Chariot stands to benefit

From the Floor question: "When will FEX start using rail to augment & de-risk their haulage solution?" | Fenix Resources

Chris Judd's Talk Ya Book: Tracking Life360 on a journey to the stars

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Good summary this is one I’m watching Pfizer did stop...

Top Stories

From the Floor question: "What is the focus of AL8 and how is management going to attract shareholders to the registry?" | Alderan Resources

From the Floor question: "Could gold be manufactured in a lab like diamonds?"

The USA's dominance requires a domestic lithium supply chain. Chariot stands to benefit

From the Floor question: "When will FEX start using rail to augment & de-risk their haulage solution?" | Fenix Resources

Chris Judd's Talk Ya Book: Tracking Life360 on a journey to the stars

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News